Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 3/20 | 1.00 |
| ▸ | HSPB1 | P04792 | 1/20 | 1.00 |
| ▸ | MAPK11 | Q15759 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gw782912X SCHEMBL6747431 | 0.95 | MAPK14 (1.00) | MAPK14CYP2C9HSPB1MAPK11 | |
| Gw782912X SCHEMBL5632189 | 0.95 | MAPK14 (1.00) | MAPK14CYP2C9HSPB1MAPK11 | |
| SCHEMBL5632508 | 0.93 | MAPK14 (1.00) | MAPK14CYP2C9HSPB1MAPK11 | |
| SCHEMBL5110583 | 0.92 | MAPK14 (0.85) | MAPK14CYP2C9HSPB1MAPK11 | |
| SCHEMBL5102820 | 0.90 | MAPK14 (0.80) | MAPK14CYP2C9HSPB1MAPK11 | |
| SCHEMBL5629868 | 0.89 | MAPK14 (0.88) | MAPK14CYP2C9HSPB1MAPK11 | |
| SCHEMBL5630096 | 0.89 | MAPK14 (0.87) | MAPK14CYP2C9HSPB1MAPK11 | |
| SCHEMBL5633077 | 0.88 | MAPK14 (1.00) | MAPK14CYP2C9HSPB1MAPK11 | |
| SCHEMBL5632201 | 0.88 | MAPK14 (0.79) | MAPK14CYP2C9HSPB1MAPK11 | |
| SCHEMBL6620463 | 0.88 | MAPK14 (1.00) | MAPK14CYP2C9HSPB1MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10441577-B2 | Medicament for treatment of liver cancer | HELMHOLTZ ZENTRUM FUER INFEKTIONSFORSCHUNG (DE) | 2019-10-15 | — | — | US | disclosed |
| US-20150079154-A1 | MEDICAMENT FOR TREATMENT OF LIVER CANCER | HELMHOLTZ-ZENTRUM FUER INFEKTIONSFORSCHUNG GMBH (DE) | 2015-03-19 | — | — | US | disclosed |
| US-20150079154-A1 | MEDICAMENT FOR TREATMENT OF LIVER CANCER | HELMHOLTZ-ZENTRUM FUER INFEKTIONSFORSCHUNG GMBH (DE) | 2015-03-19 | — | — | US | disclosed |
| US-20040267012-A1 | 5'-Carbamoyl-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2004-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040267012-A1 | 5'-Carbamoyl-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors | MAPK4, GRK4, NR4A1 | MAPK14 28/4885CYP2C9 585/4885HSPB1 3656/4885 |
| US-10441577-B2 | Medicament for treatment of liver cancer | PYGL, PFKL, GLS2 | MAPK14 523/4885CYP2C9 2391/4885HSPB1 435/4885 |
| US-20150079154-A1 | MEDICAMENT FOR TREATMENT OF LIVER CANCER | PYGL, PFKL, GLS2 | MAPK14 523/4885CYP2C9 2391/4885HSPB1 435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.